# Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01604278** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 449 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** NVA237 50 µg and indacaterol 150 µg
- **DRUG:** Placebo to NVA237 and indacaterol 150 µg

## Key facts

- **NCT ID:** NCT01604278
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 449 (ACTUAL)
- **Last updated:** 2014-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01604278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01604278, "Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01604278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*